Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM. van der Wekken AJ, et al. Among authors: schuuring e. PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017. PLoS One. 2017. PMID: 28854272 Free PMC article.
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer.
Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen ML, Takes RP, Kok K, Alvarez Marcos CA, van der Laan BF, van den Brekel MW, Langendijk JA, Kluin PM, van der Wal JE, Schuuring E. Gibcus JH, et al. Among authors: schuuring e. Clin Cancer Res. 2007 Nov 1;13(21):6257-66. doi: 10.1158/1078-0432.CCR-07-1247. Clin Cancer Res. 2007. PMID: 17975136
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de Bock GH, Wisman GB, Schuuring E, van der Zee AG. Noordhuis MG, et al. Among authors: schuuring e. Clin Cancer Res. 2009 Dec 1;15(23):7389-97. doi: 10.1158/1078-0432.CCR-09-1149. Epub 2009 Nov 17. Clin Cancer Res. 2009. PMID: 19920104
EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
Thunnissen E, Bovée JV, Bruinsma H, van den Brule AJ, Dinjens W, Heideman DA, Meulemans E, Nederlof P, van Noesel C, Prinsen CF, Scheidel K, van de Ven PM, de Weger R, Schuuring E, Ligtenberg M. Thunnissen E, et al. Among authors: schuuring e. J Clin Pathol. 2011 Oct;64(10):884-92. doi: 10.1136/jclinpath-2011-200163. J Clin Pathol. 2011. PMID: 21947301
[New 'targeted therapy' for lung cancer].
Groen HJ, Hiltermann TJ, Schuuring E, Timens W. Groen HJ, et al. Among authors: schuuring e. Ned Tijdschr Geneeskd. 2011;155(45):A4081. Ned Tijdschr Geneeskd. 2011. PMID: 22085575 Dutch.
Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.
Kerner GS, Schuuring E, Sietsma J, Hiltermann TJ, Pieterman RM, de Leede GP, van Putten JW, Liesker J, Renkema TE, van Hengel P, Platteel I, Timens W, Groen HJ; CTMM Air Force Consortium. Kerner GS, et al. Among authors: schuuring e. PLoS One. 2013 Jul 29;8(7):e70346. doi: 10.1371/journal.pone.0070346. Print 2013. PLoS One. 2013. PMID: 23922984 Free PMC article.
304 results